Restricted accessReview articleFirst published online 2025-3
Clinical,Quality of Life,and Health Care Utilization Outcomes of Switching the Administration Route of Antipsychotic Medications Among People With Schizophrenia Spectrum Disorder: A Systematic Review and Meta-Analysis
Using long-acting injectable (LAI) antipsychotic medications can improve the outcomes of patients with schizophrenia, such as reducing symptom severity and hospitalization risk. However, the outcomes of switching from oral to LAI antipsychotic medications are unclear.
Aims:
The purpose of this review is to provide a summary of the clinical, quality of life, and health care utilization outcomes of switching from oral to LAI antipsychotics among patients with Schizophrenia Spectrum Disorder.
Methods:
We thoroughly searched the PubMed, Scopus, PsycInfo, and CINAHL databases. To conduct the meta-analysis, we used the Comprehensive Meta-Analysis Program.
Results:
Forty-one articles met our inclusion criteria. After switching to LAIs, symptom severity, the number of rehospitalizations, emergency department visits, and overall health care costs were reduced. Also, social functioning significantly improved. However, no differences were observed in the frequency of outpatient visits. Pharmacy costs were increased between pre- and post-LAI initiation.
Conclusion:
Our findings support evidence that changing the route of administration of antipsychotic medications from oral to long-acting intramuscular injections can improve the clinical, quality of life, and health care utilization outcomes in people with schizophrenia. Health care practitioners might consider encouraging LAI use earlier during treatment for schizophrenia for better clinical outcomes and to reduce health care utilization associated with treatment.
AllenM. H.DanielD. G.RevickiD. A.CanusoC. M.TurkozI.FuD. J.LindenmayerJ. P. (2012). Development and psychometric evaluation of a clinical global impression for schizoaffective disorder scale. Innovations in Clinical Neuroscience, 9(1), 15–24.
2.
BeauclairL.ChueP.McCormickJ.CamachoF.LamA.LuongD. (2007). Impact of risperidone long-acting injectable on hospitalisation and medication use in Canadian patients with schizophrenia. Journal of Medical Economics, 10(4), 427–442.
3.
BeauclairL.LamA.McCormickJ.LuongD.CamachoF. (2005). Impact of Risperidone long-acting injectable on hospitalization and medication use in patients with schizophrenia. CORE, PMH23. https://core.ac.uk/download/pdf/82324872.pdf
4.
BiagiE.CapuzziE.ColmegnaF.MascariniA.BrambillaG.OrnaghiA.SantambrogioJ.ClericiM. (2017). Long-acting injectable antipsychotics in schizophrenia: Literature review and practical perspective, with a focus on aripiprazole once-monthly. Advances in Therapy, 34(5), 1036–1048.
5.
BorensteinM.HedgesL.HigginsJ.RothsteinH. (2013). Comprehensive Meta-Analysis Version 3 (CMA). SAS Institute Inc.
6.
BourinM.JollietP.HeryP.GuittonB. (1998). Is rehospitalization a measure of the efficacy of neuroleptics in the treatment of schizophrenia?International Journal of Psychiatry in Clinical Practice, 2(4), 275–278.
7.
BowtellM.RatheeshA.McGorryP.KillackeyE.O’DonoghueB. (2018). Clinical and demographic predictors of continuing remission or relapse following discontinuation of antipsychotic medication after a first episode of psychosis. A systematic review. Schizophrenia Research, 197, 9–18.
8.
ChangH.-C.TangC.-H.HuangS.-T.McCroneP.SuK.-P. (2012). A cost-consequence analysis of long-acting injectable risperidone in schizophrenia: A one-year mirror-image study with national claim-based database in Taiwan. Journal of Psychiatric Research, 46(6), 751–756.
9.
CriveraC.DeSouzaC.KozmaC. M.DiraniR. D.MaoL.MacfaddenW. (2011). Resource utilization in patients with schizophrenia who initiated risperidone long-acting therapy: Results from the Schizophrenia Outcomes Utilization Relapse and Clinical Evaluation (SOURCE). BMC Psychiatry, 11(1), Article 168.
10.
De MarinisT.SaleemP. T.GlueP.ArnoldussenW. J.TeijeiroR.LexA.LatifM. A.MedoriR. (2007). Switching to long-acting injectable risperidone is beneficial with regard to clinical outcomes, regardless of previous conventional medication in patients with schizophrenia. Pharmacopsychiatry, 40(6), 257–263.
11.
DenhamJ.AdamsonL. (1973). Long-acting phenothiazines in the prevention of relapse of schizophrenic patients. Canadian Psychiatric Association Journal, 18(3), 235–237.
12.
Devrimci-OzguvenH.AtmacaM.BaranZ.CengisizC.ÇinarC.ErolA.GençY.KaradagH.KarakülahK.KarasuU. (2019). Efficacy and safety of paliperidone palmitate treatment in patients with schizophrenia: A real-world multicenter, retrospective, mirror-image study. Journal of Clinical Psychopharmacology, 39(6), 604–610.
13.
Di LorenzoR.CameliM.PiemonteC.BolondiM.LandiG.PollutriG.SpattiniL.MorettiV.FerriP. (2018). Clinical improvement, relapse and treatment adherence with paliperidone palmitate 1-month formulation: 1-year treatment in a naturalistic outpatient setting. Nordic Journal of Psychiatry, 72(3), 214–220.
14.
DuvalS.TweedieR. (2000). A nonparametric “trim and fill” method of accounting for publication bias in meta-analysis. Journal of the American Statistical Association, 95(449), 89–98.
15.
EggerM.SmithG. D.SchneiderM.MinderC. (1997). Bias in meta-analysis detected by a simple, graphical test. British Medical Journal, 315(7109), 629–634.
16.
EmsleyR.HargarterL.BergmansP.UglešićB.SengülA. C.PetraliaA.KhannanovaA.CherubinP.SchreinerA. (2017). Once-monthly paliperidone palmitate in early stage schizophrenia–a retrospective, non-interventional 1-year study of patients with newly diagnosed schizophrenia. Neuropsychiatric Disease and Treatment, 13, 2261–2269.
17.
EnatescuV. R.DeheleanC. A.NussbaumL. A.HogeaL.HomoroganC.EnatescuI.PapavaI.MarinescuI.IfteniP.SimuM.CatalinM.Giurgi-OncuC.SirbuI. O. (2020). Study on tolerability and efficacy of paliperidone palmitate, olanzapine pamoate and risperidone long acting injection in a Romanian sample of patients with schizophrenia. Farmacia, 68(2), 242–249.
18.
EndicottJ.SpitzerR. L.FleissJ. L. (2008). Global assessment scale (GAS), global assessment of functioning (GAF) scale, social and occupational functioning assessment scale (SOFAS). In RushA. J.FirstM. B.BlackerD. B. (Eds.), Handbook of psychiatric measures (2nd ed., pp. 86–90). American Psychiatric Publishing, Inc.
19.
FangS. C.HuangC. Y.ShaoY. H. J. (2022). Long-term outcomes of early use of long-acting injectable antipsychotics in schizophrenia. The Journal of Clinical Psychiatry, 83(4), 41243.
20.
FefeuM.De MaricourtP.CachiaA.HoertelN.VacheronM.-N.WehbeE.RieuC.OlieJ.-P.KrebsM.-O.GaillardR. (2018). One-year mirror-image study of the impact of olanzapine long-acting injection on healthcare resource utilization and costs in severe schizophrenia. Psychiatry Research, 270, 205–210.
21.
FullerM.ShermockK.RussoP.SecicM.DiraniR.VallowS.FlandersS. (2009). Hospitalisation and resource utilisation in patients with schizophrenia following initiation of risperidone long-acting therapy in the Veterans Affairs Healthcare System. Journal of Medical Economics, 12(4), 317–324.
22.
GirardiP.SerafiniG.PompiliM.InnamoratiM.TatarelliR.BaldessariniR. J. (2010). Prospective, open study of long-acting injected risperidone versus oral antipsychotics in 88 chronically psychotic patients. Pharmacopsychiatry, 43(2), 66–72.
23.
HaddadP. M.BrainC.ScottJ. (2014). Nonadherence with antipsychotic medication in schizophrenia: Challenges and management strategies. Patient Related Outcome Measures, 5(5), 43–62. https://doi.org/10.2147/PROM.S42735
24.
HsiaS. L.LeckbandS. G.RaoS.JacksonE.LacroJ. P. (2017). Dosing strategies for switching from oral risperidone to paliperidone palmitate: Effects on clinical outcomes. Mental Health Clinician, 7(3), 95–100.
25.
HuangC. Y.FangS. C.ShaoY. H. J. (2021). Comparison of long-acting injectable antipsychotics with oral antipsychotics and suicide and all-cause mortality in patients with newly diagnosed schizophrenia. JAMA Network Open, 4(5), e218810.
26.
JohnsonD. A.FreemanH. (1972). Long-acting tranquillizers. The Practitioner, 208(245), 395–400.
27.
KamatS. A.OffordS.DochertyJ.LinJ.EramoA.BakerR. A.GutierrezB.KarsonC. (2015). Reduction in inpatient resource utilization and costs associated with long-acting injectable antipsychotics across different age groups of Medicaid-insured schizophrenia patients. Drugs in Context, 4, 212267.
28.
KaneJ. M.ChenA.LimS.MychaskiwM. A.TianM.WangY.SuettM.RubioJ. M. (2023). Early versus late administration of long-acting injectable antipsychotic agents among patients with newly diagnosed schizophrenia: An analysis of a commercial claims database. International Clinical Psychopharmacology, 38(4), 240–248.
29.
KaneJ. M.ZhaoC.JohnsonB. R.BakerR. A.EramoA.McQuadeR. D.DucaA. R.SanchezR.Peters-StricklandT. (2015). Hospitalization rates in patients switched from oral anti-psychotics to aripiprazole once-monthly: Final efficacy analysis. Journal of Medical Economics, 18(2), 145–154.
30.
KayS. R.FiszbeinA.OplerL. A. (1987). The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophrenia Bulletin, 13(2), 261–276.
31.
KayS. R.OplerL. A.LindenmayerJ. P. (1988). Reliability and validity of the positive and negative syndrome scale for schizophrenics. Psychiatry Research, 23(1), 99–110.
32.
KeepersG. A.FochtmannL. J.AnziaJ. M.BenjaminS.LynessJ. M.MojtabaiR.ServisM.WalaszekA.BuckleyP.LenzenwegerM. F. (2020). The American Psychiatric Association practice guideline for the treatment of patients with schizophrenia. American Journal of Psychiatry, 177(9), 868–872.
33.
KeksN.SchwartzD.HopeJ. (2019). Stopping and switching antipsychotic drugs. Australian Prescriber, 42(5), 152–157.
34.
KishimotoT.NittaM.BorensteinM.KaneJ. M.CorrellC. U. (2013). Long-acting injectable versus oral antipsychotics in schizophrenia: A systematic review and meta-analysis of mirror-image studies. The Journal of Clinical Psychiatry, 74(10), 957–965.
35.
KishimotoT.HagiK.KurokawaS.KaneJ. M.CorrellC. U. (2021). Long-acting injectable versus oral antipsychotics for the maintenance treatment of schizophrenia: A systematic review and comparative meta-analysis of randomised, cohort, and pre-post studies. The Lancet Psychiatry, 8(5), 387–404. https://doi.org/10.1016/S2215-0366(21)00039-0
36.
KmetL. M.CookL. S.LeeR. C. (2004). Standard quality assessment criteria for evaluating primary research papers from a variety of fields. Alberta Heritage Foundation for Medical Research.
37.
KoczerginskiD.ArshoffL. (2011). Hospital resource use by patients with schizophrenia: Reduction after conversion from oral treatment to risperidone long-acting injection. Healthcare Quarterly (Toronto, Ont.), 14(1), 82–87.
38.
KwonJ. S.KimS. N.HanJ.LeeS. I.ChangJ. S.ChoiJ.-S.LeeH.-J.ChoS. J.JunT.-Y.LeeS.-H. (2015). Satisfaction of immediate or delayed switch to paliperidone palmitate in patients unsatisfied with current oral atypical antipsychotics. International Clinical Psychopharmacology, 30(6), 320–328.
39.
LealA.RosillonD.MehnertA.JaremaM.RemingtonG. (2004). Healthcare resource utilization during 1-year treatment with long-acting, injectable risperidone. Pharmacoepidemiology and Drug Safety, 13(11), 811–816.
40.
LeeB. J. (2021). Admission rates, drug attitudes, and psychiatric symptoms in patients of schizophrenia after switching from paliperidone palmitate once-monthly to oral antipsychotics. Rawal Medical Journal, 46(4), 848–853.
41.
LeeD.LeeB. C.ChoiS.-H.KangD.-H.JonD.-I.JungM. H. (2020). Effects of paliperidone palmitate on healthcare utilization and costs for patients with schizophrenia: A claim-based mirror-image study in South Korea. Clinical Psychopharmacology and Neuroscience, 18(2), 303–310.
42.
LiN.ZhuoJ. M.TurkozI.MathewsM.FengY.TanW. (2019). A post hoc analysis on hospitalization risk in Asian patients with schizophrenia switching to once-monthly paliperidone palmitate from oral antipsychotics. Expert Opinion on Pharmacotherapy, 20(16), 2033–2039. https://www.tandfonline.com/doi/full/10.1080/14656566.2019.1650022
43.
LinD.Thompson-LeducP.GhelerterI.NguyenH.LafeuilleM.-H.BensonC.MavrosP.LefebvreP. (2021). Real-world evidence of the clinical and economic impact of long-acting injectable versus oral antipsychotics among patients with schizophrenia in the United States: A systematic review and meta-analysis. CNS Drugs, 35(5), 469–481.
44.
LjungdalhP. M. (2017). Non-adherence to pharmacological treatment in schizophrenia and schizophrenia spectrum disorders–an updated systematic literature review. The European Journal of Psychiatry, 31(4), 172–186.
45.
MaL.-L.WangY.-Y.YangZ.-H.HuangD.WengH.ZengX.-T. (2020). Methodological quality (risk of bias) assessment tools for primary and secondary medical studies: What are they and which is better?Military Medical Research, 7(1), 1–11.
46.
MaglioccoF.de FilippisR.AloiM.StaltariF. A.GaetanoR.Segura-GarciaC.De FazioP. (2020). Second-generation long-acting injections anti-psychotics improve executive functions in patients with schizophrenia: A 12-month real-world study. International Journal of Psychiatry in Clinical Practice, 24(2), 201–207.
47.
MahlichJ.OlbrichK.WilkA.WimmerA.Wolff-MenzlerC. (2020). Hospitalization rates and therapy costs of German schizophrenia patients who are initiated on long-acting injectable medication: A mirror-image study. Clinical Drug Investigation, 40(4), 355–375.
48.
MöllerH. J.LlorcaP. M.SacchettiE.MartinS. D.MedoriR.ParelladaE.; StoRMi Study Group. (2005). Efficacy and safety of direct transition to risperidone long-acting injectable in patients treated with various antipsychotic therapies. International Clinical Psychopharmacology, 20(3), 121–130.
49.
MoolaS.MunnZ.TufanaruC.AromatarisE.SearsK.SfetcuR.CurrieM.QureshiR.MattisP.LisyK. (2017). Chapter 7: Systematic reviews of etiology and risk. In AromatarisE.MunnZ. (Eds.), Joanna Briggs Institute reviewer’s manual (p. 5). The Joanna Briggs Institute.
50.
MundayJ.GreeneM.ChangE.HartryA.YanT.BroderM. S. (2019). Early initiation of long-acting injectable antipsychotic treatment is associated with lower hospitalization rates and healthcare costs in patients with schizophrenia: Real-world evidence from US claims data. Current Medical Research and Opinion, 35(7), 1231–1239.
51.
NafeesB.de JongeP. V. H.StullD.PascoeK.PriceM.ClarkeA.TurkingtonD. (2012). Reliability and validity of the Personal and Social Performance scale in patients with schizophrenia. Schizophrenia Research, 140(1–3), 71–76.
52.
NasrallahH.MorosiniP.GagnonD. D. (2008). Reliability, validity and ability to detect change of the Personal and Social Performance scale in patients with stable schizophrenia. Psychiatry Research, 161(2), 213–224.
53.
NewcomerJ. W.WeidenP. J.BuchananR. W. (2013). Switching antipsychotic medications to reduce adverse event burden in schizophrenia: Establishing evidence-based practice. The Journal of Clinical Psychiatry, 74(11), 1108–1120.
54.
NiazO. S.HaddadP. M. (2007). Thirty-five months experience of risperidone long-acting injection in a UK psychiatric service including a mirror-image analysis of in-patient care. Acta Psychiatrica Scandinavica, 116(1), 36–46.
55.
OhS. Y.JonD. I.HongH. J.HongN.YiJ. S.RohD.JungM. H. (2019). The impact of paliperidone palmitate on hospitalization in patients with schizophrenia: A retrospective mirror-image study. Clinical Psychopharmacology and Neuroscience, 17(4), 531.
56.
OkoliC. T. C.KappiA.WangT.MakowskiA.CooleyA. T. (2022). The effect of long-acting injectable antipsychotic medications compared with oral antipsychotic medications among people with schizophrenia: A systematic review and meta-analysis. International Journal of Mental Health Nursing, 31(3), 469–535. https://doi.org/10.1111/inm.12964
57.
OlivaresJ. M.Rodriguez-MartinezA.BurónJ. A.Alonso-EscolanoD.Rodriguez-MoralesA. (2008). Cost-effectiveness analysis of switching antipsychotic medication to long-acting injectable risperidone in patients with schizophrenia. Applied Health Economics and Health Policy, 6(1), 41–53.
58.
PageM. J.McKenzieJ. E.BossuytP. M.BoutronI.HoffmannT. C.MulrowC. D.ShamseerL.TetzlaffJ. M.AklE. A.BrennanS. E. (2021). The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. International Journal of Surgery, 88, 105906.
59.
PatelC.El KhouryA.HuangA.WangL.BashyalR. (2020). Healthcare resource utilization and costs among patients with schizophrenia switching from oral risperidone/paliperidone to once-monthly paliperidone palmitate: A Veterans Health Administration claims analysis. Current Therapeutic Research, 92, 100587. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7378858/pdf/main.pdf
60.
PatelC.EmondB.LafeuilleM.-H.Côté-SergentA.LefebvreP.TandonN.El KhouryA. C. (2020). Real-world analysis of switching patients with schizophrenia from oral risperidone or oral paliperidone to once-monthly paliperidone palmitate. Drugs-Real World Outcomes, 7(1), 19–29. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7061019/pdf/40801_2019_Article_172.pdf
61.
PengX.Ascher-SvanumH.FariesD.ConleyR. R.SchuhK. J. (2011). Decline in hospitalization risk and health care cost after initiation of depot antipsychotics in the treatment of schizophrenia. ClinicoEconomics and Outcomes Research: CEOR, 3, 9–14.
62.
PietriniF.AlbertU.BalleriniA.CalòP.MainaG.PinnaF.VaggiM.BoggianI.FontanaM.MoroC.CarpinielloB. (2019). The modern perspective for long-acting injectables antipsychotics in the patient-centered care of schizophrenia. Neuropsychiatric Disease and Treatment, 15, 1045–1060.
63.
PolonowitaA.JamesN. M. (1976). Fluphenazine decanoate maintenance in schizophrenia: A retrospective study. The New Zealand Medical Journal, 83(563), 316–318.
64.
RenX.CriveraC.SikiricaM.DiraniR.QianS.KazisL. (2011). Evaluation of health services use following the initiation of risperidone long-acting therapy among schizophrenia patients in the veterans health administration. Journal of Clinical Pharmacy and Therapeutics, 36(3), 383–389.
65.
RosaF.SchreinerA.ThomasP.SherifT. (2012). Switching patients with stable schizophrenia or schizoaffective disorder from olanzapine to risperidone long-acting injectable. Clinical Drug Investigation, 32, 267–279.
66.
RubioJ. M.SchoretsanitisG.JohnM.TiihonenJ.TaipaleH.GuinartD.MalhotraA. K.CorrellC. U.KaneJ. M. (2020). Psychosis relapse during treatment with long-acting injectable antipsychotics in individuals with schizophrenia-spectrum disorders: An individual participant data meta-analysis. The Lancet Psychiatry, 7(9), 749–761.
67.
SajatovicM.RossR.LegacyS. N.CorrellC. U.KaneJ. M.DiBiasiF.FitzgeraldH.ByerlyM. (2018a). Identifying patients and clinical scenarios for use of long-acting injectable antipsychotics–expert consensus survey part 1. Neuropsychiatric Disease and Treatment, 14, 1463–1474. https://doi.org/10.2147/NDT.S167394
68.
SajatovicM.RossR.LegacyS. N.ByerlyM.KaneJ. M.DiBiasiF.FitzgeraldH.CorrellC. U. (2018b). Initiating/maintaining long-acting injectable antipsychotics in schizophrenia/schizoaffective or bipolar disorder—Expert consensus survey part 2. Neuropsychiatric Disease and Treatment, 14, 1475–1492. https://doi.org/10.2147/NDT.S167485
69.
SchmaussM.SacchettiE.KahnJ. P.MedoriR. (2007). Efficacy and safety of risperidone long-acting injectable in stable psychotic patients previously treated with oral risperidone. International Clinical Psychopharmacology, 22(2), 85–92. https://doi.org/10.1097/YIC.0b013e3280119ddb
70.
SchwartzR. C. (2007). Concurrent validity of the Global Assessment of Functioning Scale for clients with schizophrenia. Psychological Reports, 100(2), 571–574.
71.
SiT.FanJ.WangX.WangC.XuC.ZhuoJ.FengY. (2016). A subgroup analysis of Chinese patients switched to paliperidone palmitate one-month injectable by prior oral antipsychotic treatment. Pharmacopsychiatry, 49(1), 32–41.
72.
StrunoiuL. M.DuţescuM. M.StrunoiuC. M.AlexandruD. O.PîrlogM. C.TicaA. A. (2021). The effect of switching to Long-Acting Injection (LAI) antipsychotic therapy on patients with schizophrenia. Current Health Sciences Journal, 47(2), 237–248.
73.
SuK. P.ChangH. C.TsaiS. J.YenF. C.TangC. H. (2009). Relapse and long-acting injectable risperidone: a 1-year mirror image study with a national claims database in Taiwan. Value in Health, 12, S118–S121.
74.
TanC. T.OngT. C.CheeK. T. (1981). The use of fluphenazine decanoate (Modecate) depot therapy in outpatient schizophrenics: A retrospective study. Singapore Medical Journal, 22(4), 214–218.
75.
TegelerJ.LehmannE. (1981). A follow-up study of schizophrenic outpatients treated with depot-neuroleptics. Progress in Neuro-Psychopharmacology, 5(1), 79–90.
76.
UribeE. S.NavarroF. C.MedranoA. F. G.CervantesK. I. G.VillalobosN. A. Á.RochaV. D. A.HernándezM. M.Millán AlanísJ. M.Hinojosa CavadaC. M.Zúñiga HernándezJ. A.ZambranoS. M. F. (2020). Preliminary efficacy and tolerability profiles of first versus second-generation Long-Acting Injectable Antipsychotics in schizophrenia: A systematic review and meta-analysis. Journal of Psychiatric Research, 129, 222–233.
77.
VenturaJ.CienfuegosA.BoxerO.BilderR. (2008). Clinical global impression of cognition in schizophrenia (CGI-CogS): Reliability and validity of a co-primary measure of cognition. Schizophrenia Research, 106(1), 59–69.
78.
WillisM.SvenssonM.LöthgrenM.ErikssonB.BerntssonA.PerssonU. (2010). The impact on schizophrenia-related hospital utilization and costs of switching to long-acting risperidone injections in Sweden. The European Journal of Health Economics, 11(6), 585–594.
79.
YaegashiH.KirinoS.RemingtonG.MisawaF.TakeuchiH. (2020). Adherence to oral antipsychotics measured by electronic adherence monitoring in schizophrenia: A systematic review and meta-analysis. CNS Drugs, 34(6), 579–598.
80.
ZhangF.SiT.ChiouC. F.HarrisA. W.KimC. Y.JahagirdarP.AscherS. (2015). Efficacy, safety, and impact on hospitalizations of paliperidone palmitate in recent-onset schizophrenia. Neuropsychiatric Disease and Treatment, 11, 657–668. https://doi.org/10.2147/NDT.S77778
81.
ZhdanavaM.LinD.LafeuilleM.-H.GhelerterI.MorrisonL.LefebvreP.JoshiK. (2021). Antipsychotic adherence, resource use, and costs before and after the initiation of once-monthly paliperidone palmitate therapy among medicaid beneficiaries with prior schizophrenia relapse. Clinical Therapeutics, 43(3), 535–548. https://doi.org/10.1016/j.clinthera.2021.01.011
82.
ZolezziM.AbouelhassanR.EltorkiY.HaddadP. M.NoorizadehM. (2021). Long-acting injectable antipsychotics: A systematic review of their non-systemic adverse effect profile. Neuropsychiatric Disease and Treatment, 17, 1917–1926.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
